Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2019

01-05-2019 | Review

Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients

Authors: Akshay Shetty, Adam Buch, Sammy Saab

Published in: Digestive Diseases and Sciences | Issue 5/2019

Login to get access

Abstract

As the demand for liver transplantation continues to rise, the scarcity of liver donor grafts has led to the use of extended criteria grafts for liver transplantation in select group of patients. Hepatitis C-seropositive liver grafts have been used primarily in hepatitis C-positive recipients, with studies showing non-inferior outcomes when compared to hepatitis C-negative grafts. Studies suggest that hepatitis C serology status of the donor liver does not influence the patient or graft outcomes in the recipient. These results advocate for offering hepatitis C-positive grafts to all patients awaiting liver transplantation regardless of their hepatitis C status. However, some concerns persist regarding the ethics of potentially introducing a new infection into a patient that could progress to chronic liver disease following liver transplantation. The recent approval of direct-acting antiviral therapy offers a solution to this dilemma, as it has changed the landscape of hepatitis C management by making it a curable disease. In this review, we shall discuss the current evidence regarding the use of hepatitis C-seropositive donor grafts in hepatitis C-positive and hepatitis C-negative patients.
Literature
1.
go back to reference Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18:172–253.CrossRef Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18:172–253.CrossRef
2.
go back to reference Estes C, Anstee QM, Teresa Arias-Loste M et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed Estes C, Anstee QM, Teresa Arias-Loste M et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed
4.
go back to reference Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.CrossRefPubMed Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.CrossRefPubMed
5.
go back to reference Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet. 1995;345:469–470.CrossRefPubMed Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet. 1995;345:469–470.CrossRefPubMed
6.
go back to reference Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant. 2015;15:1–28.CrossRefPubMed Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant. 2015;15:1–28.CrossRefPubMed
8.
go back to reference Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed
9.
go back to reference Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMed
10.
13.
go back to reference Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant. 2017;17:519–527.CrossRefPubMed Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant. 2017;17:519–527.CrossRefPubMed
14.
go back to reference Shaffer AA, Thomas AG, Bowring MG, et al. Changes in practice and perception of hepatitis C and liver transplantation: results of a national survey. Transpl Infect Dis. 2018;20:e12982.CrossRefPubMed Shaffer AA, Thomas AG, Bowring MG, et al. Changes in practice and perception of hepatitis C and liver transplantation: results of a national survey. Transpl Infect Dis. 2018;20:e12982.CrossRefPubMed
15.
go back to reference Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55:43–48.CrossRef Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55:43–48.CrossRef
16.
go back to reference Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297:724–732.CrossRefPubMed Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297:724–732.CrossRefPubMed
17.
go back to reference Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant. 2010;10:889–899.CrossRefPubMed Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant. 2010;10:889–899.CrossRefPubMed
18.
go back to reference Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364:236–247.CrossRefPubMed Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364:236–247.CrossRefPubMed
19.
go back to reference Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–2802.CrossRefPubMed Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–2802.CrossRefPubMed
20.
go back to reference Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65:925–929.CrossRefPubMed Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998;65:925–929.CrossRefPubMed
21.
go back to reference Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149–153.CrossRefPubMed Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117:149–153.CrossRefPubMed
22.
go back to reference Torres M, Weppler D, Reddy KR, Tzakis A. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology. 1999;117:1253.CrossRefPubMed Torres M, Weppler D, Reddy KR, Tzakis A. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology. 1999;117:1253.CrossRefPubMed
23.
go back to reference Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–394.CrossRefPubMedPubMedCentral Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–394.CrossRefPubMedPubMedCentral
24.
go back to reference Álvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc. 2012;44:1475–1478.CrossRefPubMed Álvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc. 2012;44:1475–1478.CrossRefPubMed
25.
go back to reference Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005;37:2569–2570.CrossRefPubMed Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005;37:2569–2570.CrossRefPubMed
26.
go back to reference Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73:582–587.CrossRefPubMed Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73:582–587.CrossRefPubMed
27.
go back to reference Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167–1172.CrossRefPubMed Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167–1172.CrossRefPubMed
28.
go back to reference Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV + allografts. Liver Transplant. 2006;12:1496–1503.CrossRef Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV + allografts. Liver Transplant. 2006;12:1496–1503.CrossRef
29.
go back to reference Lai JC, O’Leary JG, Trotter JF, et al. Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transplant. 2012;18:532–538.CrossRef Lai JC, O’Leary JG, Trotter JF, et al. Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transplant. 2012;18:532–538.CrossRef
30.
go back to reference Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transplant. 2001;7:762–768.CrossRef Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transplant. 2001;7:762–768.CrossRef
31.
go back to reference Peek R, Reddy KR. Hepatitis C virus-infected donors in liver transplantation. Gastroenterology. 2007;133:381–382.CrossRefPubMed Peek R, Reddy KR. Hepatitis C virus-infected donors in liver transplantation. Gastroenterology. 2007;133:381–382.CrossRefPubMed
32.
go back to reference Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–1044.CrossRefPubMed Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–1044.CrossRefPubMed
33.
go back to reference Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–1272.CrossRefPubMed Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–1272.CrossRefPubMed
34.
go back to reference Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137.CrossRefPubMedPubMedCentral Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137.CrossRefPubMedPubMedCentral
35.
go back to reference O’Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transplant Int. 2012;25:825–829.CrossRef O’Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transplant Int. 2012;25:825–829.CrossRef
36.
go back to reference Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999;29:1220–1226.CrossRefPubMed Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999;29:1220–1226.CrossRefPubMed
37.
go back to reference Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67:1673–1682.CrossRefPubMed Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67:1673–1682.CrossRefPubMed
38.
go back to reference Watanabe T, Koyama I, Shinozuka N, et al. A case of renal transplantation received from a living donor with second-generation anti-hepatitis C virus antibody positive into an anti-hepatitis C virus antibody negative recipient. Transplant Proc. 2000;32:1593–1594.CrossRefPubMed Watanabe T, Koyama I, Shinozuka N, et al. A case of renal transplantation received from a living donor with second-generation anti-hepatitis C virus antibody positive into an anti-hepatitis C virus antibody negative recipient. Transplant Proc. 2000;32:1593–1594.CrossRefPubMed
39.
go back to reference Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyo JM. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant. 2013;13:2773–2774.CrossRefPubMed Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyo JM. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant. 2013;13:2773–2774.CrossRefPubMed
40.
go back to reference Bouatou Y, Negro F, Hadaya K. ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient. Transplant Int. 2015;28:127–128.CrossRef Bouatou Y, Negro F, Hadaya K. ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient. Transplant Int. 2015;28:127–128.CrossRef
41.
go back to reference Unagami K, Ishida H, Okumi M, et al. Assessment of 4 cases of kidney transplantation from hepatitis C virus antibody-positive and RNA-negative donors to antibody-negative recipients. Transplant Direct. 2016;2:102.CrossRef Unagami K, Ishida H, Okumi M, et al. Assessment of 4 cases of kidney transplantation from hepatitis C virus antibody-positive and RNA-negative donors to antibody-negative recipients. Transplant Direct. 2016;2:102.CrossRef
42.
go back to reference Agarwal N, Davis R, Gracey D, et al. Detection of hepatitis C antibodies without viral transmission in hepatitis C-negative recipients receiving kidneys from hepatitis C-positive donors treated with direct-acting antiviral therapy. Transplantation. 2018;102:121–122. Agarwal N, Davis R, Gracey D, et al. Detection of hepatitis C antibodies without viral transmission in hepatitis C-negative recipients receiving kidneys from hepatitis C-positive donors treated with direct-acting antiviral therapy. Transplantation. 2018;102:121–122.
45.
go back to reference Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533–540.CrossRefPubMedPubMedCentral Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533–540.CrossRefPubMedPubMedCentral
46.
go back to reference Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376:2394–2395.CrossRefPubMed Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376:2394–2395.CrossRefPubMed
47.
go back to reference Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169:273–281.CrossRefPubMed Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169:273–281.CrossRefPubMed
48.
go back to reference Gudmundsson GS, Malinowska K, Robinson JA, et al. Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc. 2003;35:1536–1538.CrossRefPubMed Gudmundsson GS, Malinowska K, Robinson JA, et al. Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc. 2003;35:1536–1538.CrossRefPubMed
49.
go back to reference Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant. 2016;35:228–235.CrossRefPubMed Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant. 2016;35:228–235.CrossRefPubMed
50.
go back to reference Saberi B, Hamilton JP, Durand CM, et al. Utilization of hepatitis C RNA-positive donor liver for transplant to hepatitis C RNA-negative recipient. Liver Transplant. 2017;24:140–143.CrossRef Saberi B, Hamilton JP, Durand CM, et al. Utilization of hepatitis C RNA-positive donor liver for transplant to hepatitis C RNA-negative recipient. Liver Transplant. 2017;24:140–143.CrossRef
51.
go back to reference Campos-Varela I, Agudelo E, Sarkar M, Roberts J, Terrault N. Use of hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA negative liver transplant recipient. Transplant Infect Dis. 2018;20:e12809.CrossRef Campos-Varela I, Agudelo E, Sarkar M, Roberts J, Terrault N. Use of hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA negative liver transplant recipient. Transplant Infect Dis. 2018;20:e12809.CrossRef
52.
go back to reference Renz JF, Kin C, Kinkhabwala M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg. 2005;242:556–563. (discussion 563–555).PubMedPubMedCentral Renz JF, Kin C, Kinkhabwala M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg. 2005;242:556–563. (discussion 563–555).PubMedPubMedCentral
53.
go back to reference Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248:599–607.PubMed Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248:599–607.PubMed
54.
go back to reference Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006;244:439–450.PubMedPubMedCentral Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006;244:439–450.PubMedPubMedCentral
55.
go back to reference Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238–1246.CrossRefPubMed Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238–1246.CrossRefPubMed
56.
go back to reference Cywinski JB, Mascha EJ, You J, et al. Pre-transplant MELD and sodium MELD scores are poor predictors of graft failure and mortality after liver transplantation. Hepatol Int. 2011;5:841–849.CrossRefPubMed Cywinski JB, Mascha EJ, You J, et al. Pre-transplant MELD and sodium MELD scores are poor predictors of graft failure and mortality after liver transplantation. Hepatol Int. 2011;5:841–849.CrossRefPubMed
57.
go back to reference Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537–2546.CrossRefPubMed Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537–2546.CrossRefPubMed
58.
go back to reference Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.CrossRefPubMed Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.CrossRefPubMed
59.
go back to reference Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017;52:986–991.CrossRefPubMed Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017;52:986–991.CrossRefPubMed
60.
go back to reference Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1–6 Infection. Paper presented at: EASL International Liver Meeting, April; 2017. Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1–6 Infection. Paper presented at: EASL International Liver Meeting, April; 2017.
61.
go back to reference Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C positive grafts in hepatitis C negative liver transplant recipients is cost-effective. Clin Transplant. 2018;32:e13383.CrossRefPubMed Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C positive grafts in hepatitis C negative liver transplant recipients is cost-effective. Clin Transplant. 2018;32:e13383.CrossRefPubMed
Metadata
Title
Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients
Authors
Akshay Shetty
Adam Buch
Sammy Saab
Publication date
01-05-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5404-x

Other articles of this Issue 5/2019

Digestive Diseases and Sciences 5/2019 Go to the issue